BCYC - Bicycle Therapeutics plc Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BCYC

BICYCLE THERAPEUTICS PLC

NASDAQ

$3.73

▼ DOWN 1.58% (-0.06)

KEY STATISTICS

Market Cap$257.97 M

52w High$9.16

52w Low$3.33

Dividend Yield—

Frequency—

P/E-1.37

Volume472.23K

Shares Out.69.39M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Kevin Lee

COMPENSATION 2026

Salary$862,339

Stock Awards$1,724,800

Incentive Plan Pay$543,642

All Other Comp.$249,395

Total$6,341,473

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 23, 2019

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

288

PRICE TARGET

Target High$12.00

Target Low$12.00

Target Median$12.00

Target Consensus$12.00

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$12.22M

OCT

THU

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

42.64%

HOLDERS

139

TOP 8 OF 139 · RANKED BY POSITION SIZE

Baker Bros. Advisors LP

10.9M sh

$50.51M

Fcpm Iii Services B.V.

3.5M sh

$24.56M

Armistice Capital, LLC

3.4M sh

$15.77M

Long Focus Capital Management, LLC

3.3M sh

$15.36M

Westfield Capital Management Co LP

Acadian Asset Management LLC

PRICE

$3.73 ▼ DOWN 1.58% (−$0.06)

About Bicycle Therapeutics plc

https://www.bicycletherapeutics.com ↗

Bicycle Therapeutics plc is a UK-based clinical-stage biopharma developing novel Bicycle-based medicines for underserved diseases, with lead oncology candidates in Phase I/II trials and collaborations across oncology, ophthalmology, and other ther...

INDUSTRY

Biotechnology

A PRODUCT BICYCLE THERAPEUTICS PLC IS KNOWN FOR

Zelenectide pevedotin (BT8009)

Zelenectide pevedotin is a Bicycle Toxin Conjugate in Phase 2/3 trials targeting Nectin-4–positive advanced solid tumors, representing Bicycle Therapeutics' leading innovative cancer therapy candidate.

COMPETITORS

COMPETITOR

Bicycle Therapeutics in 2025

SENTIMENT: − NEGATIVE

RESTRUCTURING · AUGUST 2025

Bicycle Therapeutics Announces Major Restructuring, Including 25% Workforce Reduction, to Extend Financial Runway into 2028

In its second-quarter 2025 report, Bicycle Therapeutics announced a significant strategic realignment to reduce operating expenses by approximately 30%. [1, 6] This restructuring included a workforce reduction of about 25% and was aimed at extending the company's financial runway into 2028 amidst a challenging macroeconomic environment. [2, 3, 4] The announcement coincided with the news of the termination of a collaboration with Genentech. [2, 3]

RESTRUCTURING · AUGUST 2025 · IN PROGRESS

Bicycle Therapeutics Announces Major Restructuring with 25% Workforce Reduction to Extend Financial Runway and Focus on Key Oncology Programs

Bicycle Therapeutics initiated a significant strategic cost realignment in August 2025, involving a workforce reduction of approximately 25% and a projected 30% decrease in operational costs. This decision is intended to extend the company's financial runway into 2028, allowing it to prioritize and focus resources on its most promising clinical programs, particularly zelenectide pevedotin and its Bicycle® Drug Conjugates and Radioconjugates platforms.